{
    "nct_id": "NCT04647487",
    "official_title": "EMBER-2: A Phase 1, Open-Label, Preoperative Window Study Evaluating the Biological Effects of LY3484356 in Post-menopausal Women With Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer",
    "inclusion_criteria": "* Have histologically confirmed invasive ER+, HER2- breast carcinoma\n* Be willing and able to provide pre- and on-treatment tumor samples\n* Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale\n* Have adequate organ function\n* Be able to swallow capsules\n* Be a postmenopausal woman\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Have bilateral invasive breast cancer\n* Have metastatic breast cancer\n* Plan to receive concurrent neoadjuvant therapy with any other non-protocol anti-cancer therapy\n* Have had prior therapy (of any kind) for an invasive or non-invasive breast cancer\n* Have had prior radiotherapy to the ipsilateral chest wall for any malignancy\n* Have had prior anti-estrogen therapy with raloxifene, tamoxifen, aromatase inhibitor, or other selective estrogen receptor modulator (SERM), either for osteoporosis or prevention of breast cancer\n* Have had prior hormone-replacement therapy within 4 weeks of the start of study treatment\n* Have had major surgery within 28 days prior to randomization to allow for post-operative healing of the surgical wound and site(s)\n* Have certain infections such as hepatitis or tuberculosis or HIV that are not well controlled\n* Have another serious medical condition\n* Have a history of any other cancer (except nonmelanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission with no therapy for a minimum of 3 years",
    "miscellaneous_criteria": ""
}